rs1800972 — DEFB1 DEFB1 -44C>G

Promoter variant in the beta-defensin 1 gene that reduces constitutive hBD-1 expression, altering mucosal antimicrobial defense and susceptibility to inflammatory and infectious conditions

See your personal result for DEFB1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Mucosal Shield You Were Born With — and What Happens When It's Thinner

Every mucosal surface in your body — your gut lining, airways, and mouth — faces a constant barrage of bacteria, fungi, and viruses. The front line of defense is not your adaptive immune system with its antibodies and memory cells. It is an older, faster system: human beta-defensin 1 (hBD-1)11 human beta-defensin 1 (hBD-1)
a small cationic antimicrobial peptide, part of the defensin family, that kills bacteria and fungi by disrupting their membranes. Unlike inducible defensins, hBD-1 is constitutively expressed — it is always on, not waiting for infection to be detected. The DEFB1 gene encodes this peptide. The rs1800972 variant sits in the promoter region, 44 bases upstream of the transcription start site, and affects how much hBD-1 your epithelial cells produce around the clock.

The Mechanism

DEFB1 is transcribed from the minus strand of chromosome 8. Papers describe this variant as -44C>G using coding-strand notation: the C (coding strand) becomes a G, which on the plus strand corresponds to a C→G change at position 6,877,901. The GRCh38 plus-strand reference base is C — but C is the minor allele globally (~21.7% frequency). The G allele, present in ~78.3% of people, is the population major allele and is associated with higher constitutive DEFB1 expression.

The -44 position lies within the promoter, in a region that influences transcription factor binding and basal transcriptional activity. Functional studies of salivary hBD-1 protein levels have found that CG heterozygotes produce higher concentrations of hBD-1 than CC homozygotes22 CG heterozygotes produce higher concentrations of hBD-1 than CC homozygotes
Polesello V et al. Impact of DEFB1 gene regulatory polymorphisms on hBD-1 salivary concentration. Arch Oral Biol. 2015, directly linking the G allele to enhanced promoter activity. The CC genotype — two copies of the rare C allele — produces the lowest constitutive hBD-1 output.

At the gut mucosa, reduced hBD-1 is particularly consequential. hBD-1 helps maintain the antimicrobial gradient in the intestinal lumen, controls commensal bacterial overgrowth, and acts as a sentinel against opportunistic pathogens. Impaired constitutive secretion shifts the mucosal equilibrium toward bacterial and fungal permissiveness.

The Evidence

The strongest inflammatory disease association comes from a study of DEFB1 polymorphisms in Crohn's disease33 study of DEFB1 polymorphisms in Crohn's disease
Kocsis AK et al. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. Scand J Gastroenterol. 2008;43(3):299-307. The GG genotype was dramatically underrepresented among patients compared to controls (4% vs 12%), yielding an odds ratio of 3.367 for protection — equivalent to saying CC homozygotes have approximately 3.4-fold higher risk of colonic Crohn's localization compared to GG carriers.

A large study of 1,101 solid-organ transplant recipients44 1,101 solid-organ transplant recipients
Wójtowicz A et al. IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. J Infect Dis. 2015 Jul 15;212(2):232-41 found rs1800972 significantly associated with both mold colonization (p=0.001) and proven/probable invasive mold infection (p=0.0002), with the association remaining significant in multivariate regression (p=0.01). Mechanistically, C allele carriers showed reduced Aspergillus-induced IL-1β and TNF-α secretion from peripheral blood mononuclear cells, indicating that reduced hBD-1 translates into a blunted early innate response to fungal pathogens — not just a structural barrier deficit.

In chronic periodontitis, an Italian cohort of 155 controls and 439 patients found significant associations between rs1800972 and periodontitis susceptibility55 significant associations between rs1800972 and periodontitis susceptibility
Zupin L et al. LTF and DEFB1 polymorphisms are associated with susceptibility toward chronic periodontitis development. Oral Dis. 2017;23(7):882-889. A 2025 study in ankylosing spondylitis found the CG genotype associated with acute anterior uveitis (OR 9.93, 95% CI 1.76–55.7, p=0.00966 OR 9.93, 95% CI 1.76–55.7, p=0.009
Fernández-Torres J et al. DEFB1 and NLRP3 gene variants are associated with acute anterior uveitis in ankylosing spondylitis. Int Ophthalmol. 2025), with an interaction identified with NLRP3 rs3806268 suggesting an innate immune signaling axis.

Evidence quality is moderate: studies are predominantly case-control in design, sample sizes vary, and replication across independent cohorts is incomplete for some associations. The invasive mold infection data from the large transplant cohort is the strongest single dataset.

Practical Actions

The actionable consequences of reduced hBD-1 output depend on the biological context. At the gut mucosa, maintaining a dense, diverse microbiome that competes against pathogen colonization provides a functional substitute for impaired defensin output. Fermented foods containing live bacteria (specifically lactobacilli and bifidobacteria associated with mucosal colonization resistance) can reinforce this competitive exclusion.

For people with immunosuppression (transplant recipients, anyone on immunosuppressant medications), the data on invasive mold infection risk warrant proactive discussion with a treating physician about antifungal prophylaxis protocols, as institutional protocols vary and genetic risk can inform thresholds.

At the oral mucosa, the same logic as gut defense applies: antimicrobial augmentation through zinc-containing formulations targets periodontal pathogens directly. The related DEFB1 3'UTR variant rs1047031 provides further context: both promoter and post-transcriptional regulation of hBD-1 can be independently impaired.

Interactions

The DEFB1 locus carries several independently studied variants that affect hBD-1 expression at different regulatory levels. The rs1047031 3'UTR variant reduces hBD-1 through a microRNA-mediated post-transcriptional mechanism — distinct from the promoter-level effect of rs1800972. Individuals carrying risk alleles at both loci may have compound impairment of both transcriptional and post-transcriptional hBD-1 regulation, potentially additive in effect. Similarly, rs11362 (-20G>A) and rs1799946 (-52G>A) are neighboring promoter SNPs studied in the same haplotype context.

The 2025 uveitis study identified an interaction between rs1800972 and NLRP3 rs3806268, suggesting that rs1800972's effect on innate immune signaling extends beyond simple antimicrobial peptide output and involves the inflammasome pathway. This interaction candidate deserves compound action consideration once rs3806268 is in the platform.

Genotype Interpretations

What each possible genotype means for this variant.

GG Strong Mucosal Defensin Output Normal

Common genotype — full DEFB1 promoter activity and robust constitutive hBD-1 production

You have two copies of the G allele at this DEFB1 promoter position, the most common genotype globally (approximately 61% of people). The G allele at -44 is associated with higher constitutive DEFB1 promoter activity and greater basal hBD-1 protein output at mucosal surfaces. Studies of Crohn's disease found the GG genotype is the protective form — dramatically underrepresented among patients compared to controls. Your mucosal antimicrobial peptide defense through the DEFB1 constitutive pathway is expected to function at typical or above-typical levels.

CG Reduced Mucosal hBD-1 Intermediate

One risk copy — modestly reduced constitutive hBD-1 at mucosal surfaces

You carry one C allele and one G allele at this DEFB1 promoter position. Approximately 34% of people carry this heterozygous genotype globally. The C allele reduces DEFB1 promoter activity relative to the G allele; heterozygous CG carriers produce intermediate levels of constitutive hBD-1. Notably, a 2025 study found the CG genotype specifically associated with acute anterior uveitis in ankylosing spondylitis (OR 9.93), suggesting the intermediate expression state can interact with other inflammatory variants. Mucosal immune defense is mildly reduced compared to GG carriers.

CC Low Mucosal Defensin Output Reduced

Two risk copies — reduced constitutive hBD-1 with elevated susceptibility to inflammatory and infectious conditions

Beta-defensin 1 is produced continuously by epithelial cells throughout the gastrointestinal tract, airways, and oral cavity — not in response to infection, but as a permanent low-level antimicrobial coating. This constitutive output controls commensal bacterial populations, prevents pathogen adherence, and shapes the microbiome composition at mucosal surfaces. When this output is constitutively reduced by the CC genotype at the -44 position, the mucosal epithelium operates with a chronically thinner antimicrobial shield.

The Crohn's disease finding (Kocsis et al. 2008) showed the GG genotype was underrepresented among patients (4% vs 12% controls, OR 3.367 for protection), consistent with the hypothesis that reduced hBD-1 predisposes to intestinal dysregulation at the mucosal barrier. The mold infection data (Wójtowicz et al. 2015) add a mechanistic dimension: C allele carriers showed reduced Aspergillus-induced IL-1β and TNF-α secretion from peripheral blood mononuclear cells, meaning the impaired defense is not purely structural (reduced peptide output) but also functional (blunted innate cytokine response to detected fungi).

For people under immunosuppression — transplant recipients, those on long-term corticosteroids or biologic therapies — this compounded deficit (reduced defensin + blunted cytokine response) is clinically relevant and warrants proactive discussion with prescribing physicians about prophylaxis thresholds.